Program
BCG Vaccine
Also written as “BCG”, “BCG for Therapeutic Use” and “Bacillus Calmette-Guerin”.
Its studies are mostly in Non-Muscle Invasive Bladder Neoplasms · Urinary Bladder Neoplasms · Tuberculosis · Alzheimer Disease · Melanoma, led by 10 companies.
Drug pageBCG Vaccine: every studyMany companies study it; this page follows only the 16 they lead. All 103 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Chongqing Zhifei Biological Productsits history only | 41 open or running | phase 3since Mar 14, 2016 | Mar 5, 2015 | Apr 30, 2028phase 3 · NCT06747455 |
| ImmunityBioits history only | 32 open or running | phase 3since Apr 20, 2026 | May 13, 2014 | Nov 2026phase 2 · NCT06829823 |
| Chengdu CoenBiotechits history only | 21 open or running | phase 3since Jan 28, 2024 | Jan 28, 2024 | none ahead |
| AstraZenecaits history only | 11 open or running | phase 3since Jul 5, 2023 | Jul 5, 2023 | none ahead |
| Heat Biologicsits history only | 10 open or running | phase 2since Dec 5, 2013 | Dec 5, 2013 | none ahead |
| Laboratorio Pablo Cassará S.R.L.its history only | 10 open or running | phase 3since Nov 14, 2012 | Nov 14, 2012 | none ahead |
| Merckits history only | 11 open or running | phase 2since Feb 4, 2025 | Feb 4, 2025 | Sep 3, 2031phase 2 · NCT06833073 |
| Mindful Diagnostics and Therapeuticsits history only | 10 open or running | phase 2since Jun 24, 2020 | Jun 24, 2020 | none ahead |
| Pfizerits history only | 11 open or running | phase 3since Nov 13, 2019 | Nov 13, 2019 | none ahead |
| Verity Pharmaceuticals | 11 open or running | phase 3since Jul 28, 2021 | Jul 28, 2021 | Feb 2029phase 3 · NCT05037279 |
Also a collaborator on its studies: Moderna, Parexel and Proswell Medical.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Verity Pharmaceuticals only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jul 28, 2021First study: phase 3 study in Urinary Bladder NeoplasmsFirst studyNCT05037279 · 540 planned · Canada
Ahead
- Feb 2029Primary completion: phase 3 study in Urinary Bladder NeoplasmsNCT05037279
TargetBeta
A vaccine: it acts on a pathogen, not a human gene.
“A vaccine containing bacillus Calmette-Guerin (BCG), an attenuated strain of Mycobacterium bovis, with non-specific immunoadjuvant and immunotherapeutic activities”NCIt, by rule
Studies
The one study Verity Pharmaceuticals leads. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT05037279Urinary Bladder Neoplasms · Canada | 3 | Recruiting | Feb 2029 | 540 |
How it is read
Names in the registry
- “BCG”, 4 entries
- “BCG for Therapeutic Use”, 4 entries
- “Bacillus Calmette-Guerin”, 1 entry
- “BCG (50 mg) plus ANKTIVA (400 µg)”, 1 entry
- “BCG (50 mg)”, 1 entry
Conditions, from the studies’ own filings
- Non-Muscle Invasive Bladder Neoplasms, 7 studies
- Urinary Bladder Neoplasms, 5 studies
- Tuberculosis, 2 studies
- Alzheimer Disease, 1 study
- Melanoma, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.